A Study to Evaluate the Effiacy and Safety of HIP0612 in Patients With Gastric Ulcer

Phase 3 Completed 199 enrolled Hanmi Pharmaceutical Company Limited

RandomizedParallel-groupDouble-blindTreatment

Summary

A multicenter, randomized, double-blind, active-controlled, phase III study to evaluate the efficacy and safety of HIP0612 in patients with gastric ulcer.

Timeline

Start: 2023-03-06
Primary completion: 2024-12-19
Completion: 2024-12-19

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	HIP0612	Unknown	—	—
Comparator	RLD2204	Unknown	—	—

A Study to Evaluate the Effiacy and Safety of HIP0612 in Patients With Gastric Ulcer

Summary

Timeline

Drugs

Indications